A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)
Launched by ASTRAZENECA · Aug 13, 2007
Trial Information
Current as of May 08, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Confirmed malignant advanced solid tumour refractory to standard therapy or for which no suitable effective standard therapy exists.
- Exclusion Criteria:
- • Anti-cancer therapy including chemotherapy, radiotherapy, endocrine therapy, immunotherapy or use of other investigational agents within the 4 weeks prior to trial entry (or a longer period depending on the defined characteristics of the agents used).
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Brussels, , Belgium
Edinburgh, , United Kingdom
London, , United Kingdom
Amsterdam, , Netherlands
Szczecin, , Poland
Patients applied
Trial Officials
Jane Robertson, BSc, MBCHB, MD
Study Director
AstraZeneca
Dr. Johann De Bono, PhD MRCP FRCR
Principal Investigator
Royal Marsden Hospital Trust, London, UK
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials